{"text": ["AbbVie", "Falls", "3%"], "created_at": "2018-12-04 22:44:03"}
{"text": ["Roche", "Announces", "Positive", "Data", "on", "Venclexta/Venclyxto", "at", "ASH"], "created_at": "2018-12-04 22:09:41"}
{"text": ["Roche", "Announces", "Positive", "Data", "on", "Venclexta/Venclyxto", "at", "ASH"], "created_at": "2018-12-04 22:09:41"}
{"text": ["Roche", "Announces", "Positive", "Data", "on", "Venclexta/Venclyxto", "at", "ASH"], "created_at": "2018-12-04 19:39:07"}
{"text": ["IMBRUVICA\u00ae", "(ibrutinib)", "Combination", "Regimen", "Significantly", "Improved", "Survival", "Versus", "the", "Chemoimmunotherapy", "FCR", "(Fludarabine,", "Cyclophosphamide", "and", "Rituximab)", "in", "Previously", "Untreated", "and", "Younger", "Chronic", "Lymphocytic", "Leukemia", "(CLL)", "Patients;", "Late-Breaking", "Phase", "3", "Data", "at", "ASH", "2018"], "created_at": "2018-12-04 16:52:00"}
{"text": ["JNJ-AbbVie", "cancer", "drug", "Imbruvica", "succeeds", "in", "late-stage", "trial"], "created_at": "2018-12-04 16:24:32"}
{"text": ["JNJ-AbbVie", "cancer", "drug", "Imbruvica", "succeeds", "in", "late-stage", "trial"], "created_at": "2018-12-04 15:37:01"}
{"text": ["AbbVie", "Stock", "Could", "Become", "a", "New", "Happy", "Pill", "for", "Investors"], "created_at": "2018-12-04 00:07:12"}
{"text": ["AbbVie", "Stock", "Could", "Become", "a", "New", "Happy", "Pill", "for", "Investors"], "created_at": "2018-12-04 00:07:12"}
